Startseite>>Infectious Disease>> Bacterial Diseases>>Esomeprazole

Esomeprazole (Synonyms: (–)-Omeprazole, (S)-Omeprazole)

Katalog-Nr.GC48984

Esomeprazol ((S)-Omeprazol) ist ein potenter und oral wirksamer Protonenpumpenhemmer und reduziert die SÄuresekretion durch Hemmung der H+, K+-ATPase in den Belegzellen des Magens.

Products are for research use only. Not for human use. We do not sell to patients.

Esomeprazole Chemische Struktur

Cas No.: 119141-88-7

Größe Preis Lagerbestand Menge
25 mg
16,00 $
Auf Lager
50 mg
33,00 $
Auf Lager
100 mg
45,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Esomeprazole is an inhibitor of the gastric H+/K+-ATPase and the (S) enantiomer of omeprazole .1 It reversibly inhibits the activity of the H+/K+-ATPase in an enzyme assay. Esomeprazole (30 mg/kg, s.c.) inhibits histamine-induced gastric acid secretion in rats. Formulations containing esomeprazole in complex with magnesium have been used as proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux disease (GERD), H. pylori eradication, and hypersecretory conditions, as well as in the prevention of non-steroidal anti-inflammatory drug-related gastric ulcer.

1.Shin, J.M., and Sachs, G.Restoration of acid secretion following treatment with proton pump inhibitorsGastroenterology123(5)1588-1597(2002)

Bewertungen

Review for Esomeprazole

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Esomeprazole

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.